Edinburgh-based Lario Therapeutics has received $2.4 million (approximately €2m) in grant funding from The Michael J. Fox Foundation and Wellcome to expand its drug discovery platform targeting voltage-gated neuronal calcium channels implicated in several central nervous system disorders. The approach is rooted in genetics that the company believes could open new fronts in Parkinson’s disease (PD) and post-traumatic stress disorder (PTSD).
MedicalWorks from Adobe Stock